What is the 13F Pro Quality Score for PRCT?

13F Pro ranks PROCEPT BioRobotics Corp (PRCT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PRCT's current score at https://13fpro.ai/research/PRCT (free sign-up required for the full ranking).

Where does 13F Pro source PRCT data?

All PROCEPT BioRobotics Corp fundamentals and ownership data come directly from SEC EDGAR. PROCEPT BioRobotics Corp files with the SEC under CIK 1588978. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PRCT in?

PROCEPT BioRobotics Corp (PRCT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PRCT research updated on 13F Pro?

PRCT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PROCEPT BioRobotics Corp(PRCT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1588978 PRCT stock profile & AI dashboard →

13F Pro Quality Score

34.8/100

Rank #2,178 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

92.3/100

Profitability

14.7/100

Balance Sheet

12.0/100

Earnings Quality

30.0/100

Free Cash Flow

12.0/100

Institutional Flow

61.6/100

Revenue Scale

30.4/100

Dilution Risk

12.1/100

PRCT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PROCEPT BioRobotics Corp (PRCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRCT at 34.8/100 on a 32-signal composite quality model, placing it at rank #2,178 of 2,879 stocks — the bottom half of the AI-ranked universe. PRCT scores in the top quartile across revenue growth (92.3). Areas of concern include balance sheet strength (12.0) and free cash flow (12.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), PROCEPT BioRobotics Corp reports quarterly revenue of $83.1M, net income of $-31.6M, an operating margin of -39.2%. Top institutional holders of PRCT by reported 13-F value include BlackRock,, BNP Paribas Asset Management Holding S.A., VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PRCT trades on the Nasdaq exchange and files with the SEC under CIK 1588978. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PROCEPT BioRobotics Corp directly from SEC EDGAR. PROCEPT BioRobotics Corp's 13F Pro composite quality score has ranged between 8 and 85 since 2022, currently 34.8 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about PROCEPT BioRobotics Corp

Quirks, history, and lore behind PRCT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical robotics company · small-cap · listed on Nasdaq · headquartered in Redwood City, California.
2
The Numbers
Annual revenue in the low hundreds of millions and still burning cash — classic growth-stage medtech — but its installed base of robots is expanding fast across hospitals worldwide.
3
The History
Founded in the early 2010s and went public around 2021, it was built around a single surgical platform targeting one of the most common procedures performed on older men.
4
The Secret
Its entire business rests on one robot, one procedure: a minimally invasive treatment for benign prostatic hyperplasia — the enlarged prostate problem that keeps men up at night (literally).
5
The Lore
Its system uses aquablation therapy — a waterjet guided by robotics and ultrasound — meaning no heat, no lasers, and a preservation of sexual function that surgeons and patients both appreciate.
6
The Giveaway
Meet the AQUABEAM Robotic System — the only robot dedicated to treating the prostate with a high-velocity waterjet, made by a company whose very name fuses biology with robotics.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$83.1M

Net Income

Q1 2026

$-31.6M

Free Cash Flow

Q1 2026

$-41.0M

Operating Margin

Q1 2026

-39.2%

D/E Ratio

Q1 2026

0.15

AI Insight: PRCT Ratio Trends

PRCT's loss ratios narrowed sharply through mid-2025 but reversed hard in Q4 2025–Q1 2026, erasing most of the year's profitability progress.

• Operating margin improved from -50.3% in Q2 2024 to -27.8% in Q3 2025, a roughly 22pp loss-rate reduction over five quarters.

• Q4 2025 operating margin deteriorated to -40.6% and Q1 2026 held near -39.2%, reversing the prior improvement trend.

• ROIC worsened from -20.3% in Q2 2025 to -32.7% in Q1 2026, the weakest capital return reading since Q2 2024.

• Leverage (D/E) remained relatively contained, ranging 0.13–0.21 throughout the period, with no meaningful deterioration.

⚠ ROE fell to -36.4% in Q1 2026 from -20.3% in Q2 2025 — sharpest two-quarter deterioration in the dataset.

⚠ Whether Q4 2025–Q1 2026 margin deterioration reflects seasonality or structural cost re-acceleration needs clarification.

⚠ TTM operating margin of -33.9% signals the full-year loss burden remains substantial despite intermittent quarterly improvements.

Get alerted when PRCT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PROCEPT BioRobotics Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PRCT

BlackRock, Inc.
$109.1M4,362,002 sh
BNP Paribas Asset Management Holding S.A.
$77.3M3,089,378 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$60.6M2,421,362 sh
VANGUARD CAPITAL MANAGEMENT LLC
$60.0M2,399,067 sh
Chicago Capital, LLC
$54.0M2,160,587 sh
Prosight Management, LP
$48.6M1,945,000 sh
MACKENZIE FINANCIAL CORP
$43.0M1,720,738 sh
STATE STREET CORP
$38.3M1,529,631 sh
FMR LLC
$36.6M1,461,904 sh
GEODE CAPITAL MANAGEMENT, LLC
$34.1M1,363,500 sh

Fund	Value	Shares
BlackRock, Inc.	$109.1M	4,362,002
BNP Paribas Asset Management Holding S.A.	$77.3M	3,089,378
VANGUARD PORTFOLIO MANAGEMENT LLC	$60.6M	2,421,362
VANGUARD CAPITAL MANAGEMENT LLC	$60.0M	2,399,067
Chicago Capital, LLC	$54.0M	2,160,587
Prosight Management, LP	$48.6M	1,945,000
MACKENZIE FINANCIAL CORP	$43.0M	1,720,738
STATE STREET CORP	$38.3M	1,529,631
FMR LLC	$36.6M	1,461,904
GEODE CAPITAL MANAGEMENT, LLC	$34.1M	1,363,500

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PRCT on your watchlist

Track score changes the day PROCEPT BioRobotics Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PRCT a good stock to buy?

13F Pro's AI-powered analysis of PROCEPT BioRobotics Corp (PRCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRCT are available on the PRCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PRCT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PROCEPT BioRobotics Corp's investment landscape.